Tribunal Allows New Evidence In Drug Price Hiking Appeal

By Sophia Dourou (July 22, 2022, 5:18 PM BST) -- The U.K.'s competition watchdog will be able to introduce new evidence to fight the appeal of three companies attempting to overturn £100 million ($120 million) fines imposed by the regulator over the hiking of a thyroid drug's prices.

The Competition Appeal Tribunal ruled Friday that the Competition and Markets Authority can rely on new drug pricing data as it resists the appeal by drugmaker Advanz Pharma Corp. and two other companies.

"It's accepted by all parties that the evidence should be admitted…without prejudice to the argument that it would be wrong to place any weight on that evidence in view of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!